Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen.
Sachanas S, Pangalis GA, Vassilakopoulos TP, Korkolopoulou P, Kontopidou FN, Athanasoulia M, Yiakoumis X, Kalpadakis C, Georgiou G, Masouridis S, Moschogiannis M, Tsirkinidis P, Pappis V, Kokoris SI, Siakantaris MP, Panayiotidis P, Angelopoulou MK. Sachanas S, et al. Among authors: panayiotidis p. Leuk Lymphoma. 2011 Mar;52(3):387-93. doi: 10.3109/10428194.2010.534518. Epub 2010 Dec 6. Leuk Lymphoma. 2011. PMID: 21133713 Clinical Trial.
CD138 expression helps distinguishing Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL).
Kyrtsonis MC, Levidou G, Korkolopoulou P, Koulieris E, Bartzi V, Maltezas D, Pangalis GA, Kalpadakis C, Dimou M, Georgiou G, Vassilakopoulos TP, Angelopoulou MK, Salpeas V, Tsaftaridis P, Patsouris E, Panayiotidis P, Tzenou TK. Kyrtsonis MC, et al. Among authors: panayiotidis p. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):99-102. doi: 10.3816/CLML.2011.n.019. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454203
Novel M-component based biomarkers in Waldenström's macroglobulinemia.
Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM. Leleu X, et al. Among authors: panayiotidis p. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):164-7. doi: 10.3816/CLML.2011.n.039. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454223
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK. Vassilakopoulos TP, et al. Among authors: panayiotidis p. Oncologist. 2012;17(2):239-49. doi: 10.1634/theoncologist.2011-0275. Epub 2012 Jan 26. Oncologist. 2012. PMID: 22282906 Free PMC article.
Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, Panayiotidis P, Delimpasi S, Michalis E, Anargyrou K, Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, Kyrtsonis MC. Maltezas D, et al. Among authors: panayiotidis p. Hematol Oncol. 2013 Jun;31(2):96-102. doi: 10.1002/hon.2026. Epub 2012 Sep 7. Hematol Oncol. 2013. PMID: 22961993
Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study.
Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, Dimopoulos MA, Terpos E. Anargyrou K, et al. Among authors: panayiotidis p. Hemasphere. 2019 Sep 24;3(6):e303. doi: 10.1097/HS9.0000000000000303. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976477 Free PMC article.
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M, Sklirou AD, Ntanasis-Stathopoulos I, Darmani I, Briasoulis A, Kastritis E, Angelopoulou M, Baltadakis I, Panayiotidis P, Trougakos IP, Vassilakopoulos TP, Pagoni M, Dimopoulos MA. Terpos E, et al. Among authors: panayiotidis p. Cancers (Basel). 2021 Sep 6;13(17):4480. doi: 10.3390/cancers13174480. Cancers (Basel). 2021. PMID: 34503290 Free PMC article.
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Panayiotidis P, Tumyan G, Thieblemont C, Ptushkin VV, Marin-Niebla A, García-Sanz R, Le Gouill S, Stathis A, Bottos A, Hamidi H, Katz P, Perretti T, Willis JC, Buske C. Panayiotidis P, et al. Leuk Lymphoma. 2022 May;63(5):1058-1069. doi: 10.1080/10428194.2021.2015765. Epub 2022 Jan 19. Leuk Lymphoma. 2022. PMID: 35045765 Clinical Trial.
177 results